About Eligo Bioscience
Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine the CRISPR/Cas system with engineered phage capsids to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.
Company details
Funding
Total raised
$52.3M
Last stage
Series B
Investors
Founders
David Bikard
Professor at Institut Pasteur, Head of the Synthetic Biology Lab. CRISPR bacterial editing co-inventor.
Luciano Marraffini
Professor at The Rockefeller University, HHMI Investigator, CRISPR seminal inventor, and co-founder of Intellia Therapeutics.
Xavier Duportet
PhD in Synthetic Biology (MIT/INRIA). Co-founded Eligo Bioscience in 2014. MIT TR35, Forbes 30 Under 30, World Economic Forum Technology Pioneer, and Termeer Fellow.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.